StockNews.com Begins Coverage on Senseonics (NYSE:SENS)

StockNews.com started coverage on shares of Senseonics (NYSE:SENS) in a research report issued on Wednesday. The firm set a “sell” rating on the stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $2.00 price objective on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Stock Up 2.1 %

Shares of SENS opened at $0.35 on Wednesday. The firm has a market cap of $187.40 million, a P/E ratio of -2.69 and a beta of 0.79. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.89 and a current ratio of 3.11. Senseonics has a 52 week low of $0.32 and a 52 week high of $0.75. The firm’s 50-day simple moving average is $0.37 and its 200 day simple moving average is $0.41.

Senseonics (NYSE:SENS) last posted its earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The company had revenue of $4.87 million for the quarter, compared to the consensus estimate of $4.86 million. Senseonics had a negative return on equity of 299.69% and a negative net margin of 335.15%. On average, analysts forecast that Senseonics will post -0.13 earnings per share for the current year.

Hedge Funds Weigh In On Senseonics

A number of hedge funds have recently added to or reduced their stakes in SENS. State Board of Administration of Florida Retirement System bought a new position in Senseonics in the 1st quarter valued at about $91,000. Virtu Financial LLC bought a new position in Senseonics in the first quarter valued at approximately $162,000. Cubist Systematic Strategies LLC lifted its stake in Senseonics by 25.9% during the second quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Senseonics by 16.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after acquiring an additional 51,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock valued at $483,000 after purchasing an additional 211,128 shares during the last quarter. Institutional investors own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.